|This Slide: #14 of 100|
Slide #14. Epirus Biopharmaceuticals, Inc. — Zalicus
Epirus Biopharmaceuticals, Inc.
Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, and Zalicus Inc. (NASDAQ:ZLCS) (Zalicus), announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals, Inc., and will operate under the leadership of the Epirus management team with Amit Munshi serving as the president and chief executive officer. In addition, Dr. Mark H.N. Corrigan will serve as chairman of the company's board of directors, which will have representatives from both the existing Epirus and Zalicus boards.
Open the ZLCS Page at The Online Investor »
Open the ZLCS Page at The Online Investor (in a new window) »
Free ZLCS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (4.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite